Moderna said Thursday its coronavirus vaccine is 96% effective in children ages 12-17, according to early data released from the company in its first-quarter earnings statement.
The drugmaker also plans to submit data on its vaccine for adults to the Food and Drug Administration for full approval this month, CNBC reported.
In teenagers, Modera said its original vaccine was generally well tolerated with no serious safety concerns to date. The roughly 3,000 participants in the clinical trial were ages 12 to 17.
Company officials also said its coronavirus vaccine helped drive its first-ever quarter of profitability since Moderna was founded in 2010.
However, President Biden said Wednesday that the U.S. would back waiving patent rights for coronavirus vaccines, which would undoubtedly affect the company’s bottom line.